Foreign firms showed mixed reactions to the decision, with some willing to offload a 5% stake while others were not ...

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

Sanofi India Limited ( ($IN:SANOFI) ) has issued an update. Sanofi India Limited reported a 2% decline in net sales year-to-date but achieved a 6% ...

He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

BENGALURU] European stocks logged their biggest one-day drop in over three months on Friday (Aug 1), at the end of a busy ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decrease 25% in ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Among individual stocks, Italy's Campari was the top gainer on the STOXX 600 index, adding 8.6% after reporting an increase ...

Wacker commissions new ultra-pure polysilicon plant in Burghausen, Germany; Thermo Fisher Scientific to acquire Sanofi plant in New Jersey; Kuraray to expand production capacity for optical films in J ...

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate ...